FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer (MIBC)
RegulatoryapprovedKEYTRUDAKEYTRUDA QLEXPadcevPositive
AI Analysis
Summary
FDA approved KEYTRUDA and KEYTRUDA QLEX, each combined with Padcev, for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer in adults. This represents a significant expansion of Merck's KEYTRUDA franchise in urothelial cancer.
Outcome Details
FDA approved KEYTRUDA and KEYTRUDA QLEX, each in combination with Padcev, for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer in adults
Importance:9/10
Sentiment:
0.95
FDA approvaloncologybladder cancerimmunotherapycombination therapy
Read the original article
Published by yahoo_finance on July 10, 2026 6:10 PM